HRL — Hormel Foods Corporation

The tape is unambiguously negative as of 2026-09-13: HRL is down 4.5% in one week, 15.7% in one month, 16.9% in three months, and RSI has collapsed to 23.2. The proximate causes are concrete - Q3 FY2026 net sales fell 2.4% YoY to $2.96B and missed the ~$3.04B consensus, management cut full-year sales guidance to $12.1-$12.2B from $12.2-$12.5B, and on 2026-09-11 S&P Global revised its outlook to negative (affirming A-) citing adjusted leverage of 1.8x. Even the Q3 adjusted EPS beat ($0.37 vs. $0.35) and 60bp adjusted margin expansion to 9% were drowned out by the top-line miss and the guidance trim. Sentiment is being driven by the revenue line, not the cost line.

Revenue is structurally stagnant, not merely soft in one quarter. Quarterly sales have oscillated in a tight $2.89B-$3.20B band for twelve straight quarters: Q4 FY2023 $3.198B, Q4 FY2024 $3.138B, Q4 FY2025 $3.186B - essentially flat over two years. More concerning, YoY growth has decelerated through FY2026: +1.5% (Q4 FY25), +1.3% (Q1 FY26), +2.6% (Q2 FY26), then -2.4% (Q3 FY26). That is a genuine deceleration turning negative, not a blip. GAAP earnings look catastrophic (TTM EPS $0.622; Q4 FY2025 showed -$0.10 EPS on a $2.2M operating income quarter, and Q3 FY2026 posted just $110.9M operating income vs. ~$230M typical), but these are one-off-charge quarters - adjusted EPS of $0.37 in Q3 FY26 beat consensus, and FY2026 adjusted EPS guidance of $1.45-$1.51 implies 6-10% growth. The offsetting positive: cash generation is improving hard - TTM free cash flow is $780.8M vs. $627.7M a year earlier (+24%), and the accruals ratio is a healthy -1.36%, meaning earnings are not running ahead of cash. Verdict: flat-to-declining top line (structural), modestly improving adjusted margins and cash flow (cyclical recovery in cost control), GAAP noise from charges masking both.

Fair-to-slightly-cheap, but only if you normalize the charges. The headline TTM P/E of 32.65x looks expensive, but it is garbage-in: TTM EPS of $0.622 includes two charge-distorted quarters (Q4 FY25 -$0.10, Q3 FY26 $0.11). On forward numbers the picture flips - $20.57 divided by FY2027 consensus EPS of $1.486 is 13.9x, and against FY2026 adjusted guidance midpoint ~$1.48 it is also ~13.9x, versus a 5-year average P/E of 24.25x. Price/sales of 0.93 is well below the 5-year average of 1.60, P/B is 1.44, and EV/EBITDA is 15.3x on depressed TTM EBITDA (closer to ~9.6x on normalized ~$1.34B EBITDA). The PEG of -0.604 is meaningless here because it uses shrinking GAAP TTM earnings. Read plainly: the market has de-rated HRL from a premium staple multiple to roughly a no-growth packaged-food multiple, which is defensible given flat revenue - the question is whether it has over-corrected on a company still growing adjusted EPS 6-10% with a 4.77% dividend yield and a rock-solid balance sheet (D/E 0.36, current ratio 1.88).

This is a classic earnings-quality information gap. The market appears to be anchoring on ugly GAAP figures - a 32.65x TTM P/E and collapsing reported EPS - while the adjusted numbers show 6-10% EPS growth and margin expansion. That disconnect is partly the market's skepticism (adjustments are only worth something if they convert to cash, and Q3's adjusted beat earned zero credit because revenue missed) and partly a legitimate gap the company can close by executing. The key tell to watch: adjusted EPS growth of 6-10% is being delivered through cost control and supply-chain efficiency against a shrinking revenue base - that is a finite source of upside. Until revenue stabilizes, the market will keep valuing HRL as a melting-ice-cube staple and the 13.9x forward multiple is the correct price, not a mispricing. If revenue turns positive while adjusted margins hold near 9%, a re-rating to the mid-teens multiple becomes credible; if revenue keeps declining, mid-teens is a ceiling, not a base.

Deeply oversold inside a confirmed downtrend. As of 2026-09-13, RSI(14) was 23.17 - well below the 30 oversold threshold - and price stood 9.06% below the 20-day SMA, 14.50% below the 50-day SMA, and 12.12% below the 200-day SMA. All three moving-average readings are negative and the 50-day gap is the widest, which is the signature of an accelerating decline rather than a range. Momentum confirms it: -4.5% over one week, -15.66% over one month, -16.89% over three months, -9.14% over six months. Trading at $20.57 against a 52-week range of $19.70-$26.60, there is almost no support left beneath the stock until the range low at $19.70. Entry-timing implication: oversold conditions can produce a sharp reflex bounce, but there is no evidence of a base - buying purely on RSI 23 is catching a falling knife. A more disciplined trigger would be an RSI reclaim above 30-35 and a close back above the 20-day SMA, or a successful retest of $19.70 that holds.

• Protein and nut input cost inflation (pork, beef, tree nuts, logistics) continues to compress gross margin, which sits at 15.7% TTM and reached only 15.9% in Q3 FY2026 - a structurally lower level than the pre-COVID era.
• Private-label trade-down: consumers under wallet pressure are shifting to store brands, directly hitting branded retail volumes - retail sales fell 4% in Q3 FY2026 and private-label snack-nut volumes were explicitly soft.
• Credit and cost-of-capital pressure: S&P's 2026-09-11 negative outlook (A- affirmed) on 1.8x adjusted leverage raises the risk of a downgrade and increases scrutiny on capital allocation, buybacks, and dividend growth.
• Defensive/low-beta positioning: HRL's beta of 0.315 and 4.77% dividend yield make it a candidate beneficiary of any rotation into consumer staples if rates fall or equity volatility rises - a genuine potential tailwind that has not yet shown up in the price.
• Trade and international exposure: export demand for pork/turkey and the recently completed Ceratti Brazil divestiture reshape the international segment's growth and FX sensitivity going forward.

• Q4 FY2026 earnings (historically late November/early December 2026): the first real test of whether the tightened $1.45-$1.51 adjusted EPS guidance is met and, more importantly, whether revenue growth stops being negative.
• New CEO John Ghingo's strategic plan - appointed late July 2026 - plus a new CFO (Ash Bhumbla) and Chief Accounting Officer (Paul Kuehneman); any portfolio reshaping, further divestitures, or a formal turnaround roadmap would be a re-rating catalyst.
• Continued supply-chain and cost-efficiency savings: Q3 FY2026 already showed +60bp adjusted operating margin expansion to 9%, and sustained delivery would validate the adjusted earnings story over the GAAP noise.
• Potential S&P outlook stabilization back to stable if leverage trends below 1.8x - a dated, identifiable sentiment inflection point.
• An oversold technical rebound: with RSI at 23.2 and the stock $1.87 above its 52-week low, any positive fundamental headline could trigger a sharp mean-reversion move.

• Revenue decline proves structural, not cyclical: three years of essentially flat-to-down sales (~$12B run-rate) with private-label competition intensifying means the adjusted EPS growth engine (cost control) eventually runs out of fuel.
• Margin recovery stalls: with TTM operating margin at 4.7% and EBITDA margin below 11%, elevated pork, beef, nut, and logistics costs could keep the company below the 9% adjusted operating margin it just achieved.
• Credit deterioration: S&P's negative outlook (2026-09-11) on 1.8x leverage could become a downgrade, raising borrowing costs and potentially constraining the dividend or buyback.
• Leadership execution risk: a new CEO, CFO, and Chief Accounting Officer all within roughly two months is significant senior turnover during a turnaround - strategy could stall or change direction mid-stream.
• Value-trap risk: at 13.9x forward earnings and 0.93x sales, the stock looks cheap, but if FY2027 consensus EPS of $1.486 proves optimistic against a shrinking revenue base, the multiple is not actually cheap.
• Dividend sustainability if FCF deteriorates - currently covered comfortably at $780.8M TTM FCF, but that depends on the cash conversion persisting.

Not a buy here, but not a sell either - this is a show-me turnaround with a cheap-looking multiple and no confirming evidence yet. The bull case is real: a rock-solid balance sheet (D/E 0.36, current ratio 1.88, $840M cash), $780.8M of TTM free cash flow growing 24% YoY, a 4.77% dividend, adjusted EPS guided to 6-10% growth, and a 13.9x forward P/E versus a 24.25x five-year average - all with RSI at 23.2. The bear case is equally real: revenue is flat-to-declining over three years, Q3 FY2026 sales fell 2.4% and missed, guidance was cut, private-label pressure is intensifying, S&P went negative on leverage, and the entire adjusted-earnings story rests on cost control rather than growth. The honest read is that the cheap multiple is mostly deserved compensation for a stagnant top line, and the deeply oversold technicals offer no evidence of a bottom. Income-oriented investors could justify drip-feeding at these levels for the yield and balance-sheet safety; total-return investors should wait for either revenue stabilization or a technical base above the 20-day SMA before committing.

I applied a 15.0x multiple to FY2027 consensus adjusted EPS of $1.486 (= $22.29), justified by HRL's 6-10% adjusted EPS growth, 4.77% dividend yield, and fortress balance sheet, but discounted well below its 24.25x five-year average P/E to reflect a structurally flat top line. Cross-checking with EV/EBITDA: ~$12.15B FY2026 revenue at a ~9% adjusted operating margin plus ~$250M D&A gives ~$1.34B normalized EBITDA; 10.5x on that (a modest discount to the ~12x packaged-food average given the growth profile) yields ~$14.1B EV, or ~$22.83 per share after subtracting ~$1.51B net debt. Blending the two methods (average ~$22.56) gives my fair value of $22.50, roughly 9% above the 2026-09-13 price of $20.57 but below the two-analyst consensus target of $24.67 - the gap reflects my lower multiple on the same earnings, because I do not think a company with negative revenue growth deserves a mid-teens multiple until the top line stabilizes.